Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

First Posted Date
2018-08-01
Last Posted Date
2021-10-04
Lead Sponsor
University of California, San Francisco
Target Recruit Count
25
Registration Number
NCT03609827
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

High Dose Ascorbic Acid for Plasma Cell Disorders

Phase 1
Recruiting
Conditions
Multiple Myeloma
Interventions
Other: Ascorbate
Drug: Melphalan
First Posted Date
2018-07-26
Last Posted Date
2024-11-12
Lead Sponsor
Christopher Strouse
Target Recruit Count
9
Registration Number
NCT03602235
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2018-07-11
Last Posted Date
2021-10-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
19
Registration Number
NCT03583424
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

First Posted Date
2018-07-09
Last Posted Date
2020-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT03579927
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

First Posted Date
2018-07-09
Last Posted Date
2024-06-06
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
48
Registration Number
NCT03579875
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

First Posted Date
2018-06-27
Last Posted Date
2022-06-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
100
Registration Number
NCT03570983
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

First Posted Date
2018-04-24
Last Posted Date
2020-07-24
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT03506802
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

First Posted Date
2018-04-11
Last Posted Date
2024-02-22
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
36
Registration Number
NCT03494569
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

First Posted Date
2018-02-08
Last Posted Date
2020-10-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
3
Registration Number
NCT03426969
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

First Posted Date
2018-01-26
Last Posted Date
2024-05-24
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
265
Registration Number
NCT03412565
Locations
🇺🇸

Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States

and more 60 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy